These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 31264136)
1. Tumor Clearance Analysis on a Cancer Chemo-Immunotherapy Mathematical Model. Valle PA; Coria LN; Salazar Y Bull Math Biol; 2019 Oct; 81(10):4144-4173. PubMed ID: 31264136 [TBL] [Abstract][Full Text] [Related]
2. The four-dimensional Kirschner-Panetta type cancer model: How to obtain tumor eradication? Krishchenko AP; Starkov KE Math Biosci Eng; 2018 Oct; 15(5):1243-1254. PubMed ID: 30380309 [TBL] [Abstract][Full Text] [Related]
3. Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations. de Pillis LG; Gu W; Radunskaya AE J Theor Biol; 2006 Feb; 238(4):841-62. PubMed ID: 16153659 [TBL] [Abstract][Full Text] [Related]
4. Mathematical Modelling for the Role of CD4 Makhlouf AM; El-Shennawy L; Elkaranshawy HA Comput Math Methods Med; 2020; 2020():7187602. PubMed ID: 32148558 [TBL] [Abstract][Full Text] [Related]
5. An extended mathematical model of tumor growth and its interaction with the immune system, to be used for developing an optimized immunotherapy treatment protocol. Qomlaqi M; Bahrami F; Ajami M; Hajati J Math Biosci; 2017 Oct; 292():1-9. PubMed ID: 28713023 [TBL] [Abstract][Full Text] [Related]
7. Modeling Pancreatic Cancer Dynamics with Immunotherapy. Hu X; Ke G; Jang SR Bull Math Biol; 2019 Jun; 81(6):1885-1915. PubMed ID: 30843136 [TBL] [Abstract][Full Text] [Related]
8. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Zhou T; Damsky W; Weizman OE; McGeary MK; Hartmann KP; Rosen CE; Fischer S; Jackson R; Flavell RA; Wang J; Sanmamed MF; Bosenberg MW; Ring AM Nature; 2020 Jul; 583(7817):609-614. PubMed ID: 32581358 [TBL] [Abstract][Full Text] [Related]
9. Periodically Pulsed Immunotherapy in a Mathematical Model of Tumor, CD4 Wei HC; Yu JL; Hsu CY Comput Math Methods Med; 2017; 2017():2906282. PubMed ID: 29250133 [TBL] [Abstract][Full Text] [Related]
10. Mathematical model of tumor-immune surveillance. Mahasa KJ; Ouifki R; Eladdadi A; Pillis L J Theor Biol; 2016 Sep; 404():312-330. PubMed ID: 27317864 [TBL] [Abstract][Full Text] [Related]
11. Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer. Bödder J; Zahan T; van Slooten R; Schreibelt G; de Vries IJM; Flórez-Grau G Front Immunol; 2020; 11():631713. PubMed ID: 33679726 [TBL] [Abstract][Full Text] [Related]
12. Mathematical modeling of the effect of boosting tumor infiltrating lymphocyte in immunotherapy. Kartono A; Subiyanto Pak J Biol Sci; 2013 Oct; 16(20):1095-103. PubMed ID: 24506008 [TBL] [Abstract][Full Text] [Related]
13. A mathematical prognosis model for pancreatic cancer patients receiving immunotherapy. Li X; Xu JX J Theor Biol; 2016 Oct; 406():42-51. PubMed ID: 27338302 [TBL] [Abstract][Full Text] [Related]
14. Biological effects of IL-15 on immune cells and its potential for the treatment of cancer. Zhang S; Zhao J; Bai X; Handley M; Shan F Int Immunopharmacol; 2021 Feb; 91():107318. PubMed ID: 33383444 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment. Carnevalli LS; Ghadially H; Barry ST Front Immunol; 2021; 12():633685. PubMed ID: 33953710 [TBL] [Abstract][Full Text] [Related]
16. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy. Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B Front Immunol; 2018; 9():2905. PubMed ID: 30619269 [TBL] [Abstract][Full Text] [Related]
17. The interaction of NK cells and dendritic cells in the tumor environment: how to enforce NK cell & DC action under immunosuppressive conditions? Jacobs B; Ullrich E Curr Med Chem; 2012; 19(12):1771-9. PubMed ID: 22414086 [TBL] [Abstract][Full Text] [Related]
18. A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8 Watkins-Schulz R; Tiet P; Gallovic MD; Junkins RD; Batty C; Bachelder EM; Ainslie KM; Ting JPY Biomaterials; 2019 Jun; 205():94-105. PubMed ID: 30909112 [TBL] [Abstract][Full Text] [Related]
19. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy. Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476 [TBL] [Abstract][Full Text] [Related]
20. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. Gao X; Wang X; Yang Q; Zhao X; Wen W; Li G; Lu J; Qin W; Qi Y; Xie F; Jiang J; Wu C; Zhang X; Chen X; Turnquist H; Zhu Y; Lu B J Immunol; 2015 Jan; 194(1):438-45. PubMed ID: 25429071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]